FDA Claims Zofran may be Associated with Abnormal Heart Rhythms

Posted by Firm Staff on Jul 12, 2016 12:46:40 PM

In 2011, the U.S. Food and Drug Administration (FDA) issued a safety communication stating the anti-nausea drug Zofran may increase the risk of potentially fatal abnormal heart rhythms. Patients at particular risk of changes in the electrical activity of the heart include those with underlying heart conditions. 

Read More

Topics: Health, Medical, Medical News, FDA, The Law Offices of Foster & Houston, FANDHLAW, Zofran Lawsuit, Zofran, Ryan Foster, Foster & Houston

Contact Foster & Houston

More to Read